Page
%P
-
Article
Open AccessMulti-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases
Melanoma brain metastases (MBM) are clinically challenging to treat and exhibit variable responses to immune checkpoint therapies. Prior research suggests that MBM exhibit poor tumor immune responses and are e...
-
Article
Open AccessImpact of COVID-19 in patients on active melanoma therapy and with history of melanoma
COVID-19 particularly impacted patients with co-morbid conditions, including cancer. Patients with melanoma have not been specifically studied in large numbers. Here, we sought to identify factors that associa...
-
Article
A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy
Background The CXCR4 chemokine receptor promotes tumor survival through mechanisms that include suppressing antitumor immune responses. Mavorixafor (X4P-001) is an oral, selective, allosteric CXCR4 inhibitor that...
-
Article
Open AccessThe “Great Debate” at Melanoma Bridge 2020: December, 5th, 2020
The Great Debate session at the 2020 Melanoma Bridge virtual congress (December 3rd–5th, Italy) featured counterpoint views from experts on five specific controversial issues in melanoma. The debates considere...
-
Article
Open AccessIntegrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma
Sarcomatoid and rhabdoid (S/R) renal cell carcinoma (RCC) are highly aggressive tumors with limited molecular and clinical characterization. Emerging evidence suggests immune checkpoint inhibitors (ICI) are pa...
-
Article
Checkpoint inhibitor immunotherapy in kidney cancer
Kidney cancer has unique features that make this malignancy attractive for therapeutic approaches that target components of the immune system. Immune checkpoint inhibition is a well-established part of kidney ...
-
Book and Reference Work
-
Reference Work Entry In depth
Evolving Role of Chemotherapy-Based Treatment of Metastatic Melanoma
For many years the mainstay of treatment for metastatic melanoma, chemotherapy is much less used today. Although a small minority of patients benefit from cytotoxic agents, responses are often only short-lived...
-
Reference Work Entry In depth
Cytokines (IL-2, IFN, GM-CSF, etc.) Melanoma
Treatment of advanced stage melanoma has recently undergone a revolutionary change. Prior to 2011 dacarbazine and interleukin-2 were the only treatment options with both demonstrating no impact on overall surv...
-
Reference Work Entry In depth
Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma
Recent advances in molecular targeted therapy and immunotherapy have revolutionized the treatment of metastatic melanoma. Combined BRAF inhibitors and MEK inhibitors have been approved for the treatment of BRA...
-
Article
Open AccessThe Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a prog...
-
Article
Open AccessSafety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection
Patients with chronic viral infections including human immunodeficiency virus (HIV), hepatitis B (HBV) and hepatitis C (HCV) are at increased risk of develo** malignancies. The safety and efficacy of ICI the...
-
Article
Open AccessA case of checkpoint inhibitor-induced celiac disease
Immune checkpoint inhibitors (ICIs) have now become standard of care treatment for many malignancies. ICIs are associated with unique immune mediated adverse events (irAEs) due to dysregulation of immune activ...
-
Article
Open AccessThe promise of Immuno-oncology: implications for defining the value of cancer treatment
The rapid development of immuno-oncology (I-O) therapies for multiple types of cancer has transformed the cancer treatment landscape and brightened the long-term outlook for many patients with advanced cancer....
-
Article
Open AccessExceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors
Balancing the potential for durable remissions with autoimmune-like toxicities is a key clinical challenge in the use of immune checkpoint inhibitors (ICI). Certain toxicities are associated with an increased ...
-
Living Reference Work Entry In depth
Cytokines (IL-2, IFN GM-CSF etc) Melanoma
Treatment of advanced stage melanoma has recently undergone a revolutionary change. Prior to 2011 dacarbazine and interleukin-2 were the only treatment options with both demonstrating no impact on overall surv...
-
Living Reference Work Entry In depth
Evolving Role of Chemotherapy-Based Treatment of Metastatic Melanoma
For many years the mainstay of treatment for metastatic melanoma, chemotherapy is much less used today. Although a small minority of patients benefit from cytotoxic agents, responses are often only short-lived...
-
Living Reference Work Entry In depth
Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma
Recent advances in molecular targeted therapy and immunotherapy have revolutionized the treatment of metastatic melanoma. Combined BRAF inhibitors and MEK inhibitors have been approved for the treatment of BRA...
-
Article
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
In the version of this article originally published, there was an error in Fig. 2n. The top line of the HR comparison chart originally was Atezo + bev vs sun. It should have been Atezo + bev vs atezo. The erro...
-
Article
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib in 305 patients with treatment-naive metastatic ren...
